News - OBI Pharma 台灣浩鼎

2023.Apr.20

Corporate

Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

2023.Apr.10

Corporate

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

2022.Jul.05

Corporate

OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs

2022.Jun.06

Corporate

Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424

2022.May.17

Corporate

OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

2022.Apr.08

Corporate

Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

2022.Apr.07

Corporate

OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

2022.Feb.22

Corporate

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

2022.Feb.08

未分類

Corporate

OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

2022.Jan.25

Corporate

OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

Announcements

Latest announcements

Events

Latest events